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Abstract
Background: Leishmania represent a complex of important human pathogens that belong to the systematic
order of the kinetoplastida. They are transmitted between their human and mammalian hosts by different
bloodsucking sandfly vectors. In their hosts, the Leishmania undergo several differentiation steps, and their
coordination and optimization crucially depend on numerous interactions between the parasites and the
physiological environment presented by the fly and human hosts. Little is still known about the signalling networks
involved in these functions. In an attempt to better understand the role of cyclic nucleotide signalling in Leishmania
differentiation and host-parasite interaction, we here present an initial study on the cyclic nucleotide-specific
phosphodiesterases of Leishmania major.
Results: This paper presents the identification of three class I cyclic-nucleotide-specific phosphodiesterases
(PDEs) from L. major, PDEs whose catalytic domains exhibit considerable sequence conservation with, among
other, all eleven human PDE families. In contrast to other protozoa such as Dictyostelium, or fungi such as
Saccharomyces cerevisiae, Candida ssp or Neurospora, no genes for class II PDEs were found in the Leishmania
genomes. LmjPDEA contains a class I catalytic domain at the C-terminus of the polypeptide, with no other
discernible functional domains elsewhere. LmjPDEB1 and LmjPDEB2 are coded for by closely related, tandemly
linked genes on chromosome 15. Both PDEs contain two GAF domains in their N-terminal region, and their
almost identical catalytic domains are located at the C-terminus of the polypeptide. LmjPDEA, LmjPDEB1 and
LmjPDEB2 were further characterized by functional complementation in a PDE-deficient S. cerevisiae strain. All
three enzymes conferred complementation, demonstrating that all three can hydrolyze cAMP. Recombinant
LmjPDEB1 and LmjPDEB2 were shown to be cAMP-specific, with Km values in the low micromolar range. Several
PDE inhibitors were found to be active against these PDEs in vitro, and to inhibit cell proliferation.
Conclusion: The genome of L. major contains only PDE genes that are predicted to code for class I PDEs, and
none for class II PDEs. This is more similar to what is found in higher eukaryotes than it is to the situation in
Dictyostelium or the fungi that concomitantly express class I and class II PDEs. Functional complementation
demonstrated that LmjPDEA, LmjPDEB1 and LmjPDEB2 are capable of hydrolyzing cAMP. In vitro studies with
recombinant LmjPDEB1 and LmjPDEB2 confirmed this, and they demonstrated that both are completely cAMP-
specific. Both enzymes are inhibited by several commercially available PDE inhibitors. The observation that these
inhibitors also interfere with cell growth in culture indicates that inhibition of the PDEs is fatal for the cell,
suggesting an important role of cAMP signalling for the maintenance of cellular integrity and proliferation.
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Human pathogenic leishmanias are family of protozoa
that are transmitted by female sandflies to mammalian
hosts such as dogs, rodents, or humans. Three clinical
forms of human leishmaniases are distinguished: visceral
(caused e.g. by Leishmania donovani), mucocutaneous (e.g.
L. braziliensis), and cutaneous leishmaniasis (e.g. L.
major). All three exhibit different immunopathologies and
different degrees of morbidity and mortality. Visceral
leishmaniasis (Kala Azar) leads to progressive hepat-
osplenomegaly and is fatal if untreated. The classical
mucocutaneous leishmaniasis (Espundia) leads to pro-
gressive destruction of nasal and buccal mucosa, eventu-
ally destroying nose, lips, palate and pharynx. Cutaneous
leishmaniasis (oriental sore), is a localized, frequently
self-healing infection of the skin at the site of the initial
insect-bite, leaving ugly scars and life-long immunity [1-
3]. The human leishmaniases are occurring worldwide,
with endemic regions spreading and case numbers
strongly increasing over the last ten years. About 12 mil-
lion people are infected, with about 2 million new cases
occcurring annually. Chemotherapy of the leishmaniases
is in a very unsatisfactory state, and research into new drug
targets and the development of novel, more effective and
less toxic drugs is an urgent priority [4,5].
The Leishmania parasite undergoes a complex life cycle
containing two different hosts, the fly vectors (Lutzomya
spp, Phlebotomus ssp) and the human or mammalian
hosts. Metacyclic parasites injected by the fly into the bite
wound rapidly invade macrophages and differentiate
morphologically and metabolically into intracellular
amastigote forms. When taken up by a fly, the parasites
transform in the gut of the fly into flagellated promastig-
ote forms that eventually migrate to the salivary gland of
the fly, where they differentiate again into infectious met-
acyclics [6]. During all these differentiation steps, the par-
asites are in continuous, intense contact with structures
and metabolites of their hosts, requiring a repertoire of
sensing and adaptation mechanisms in order to coordi-
nate differentiation with host environment. Surprisingly
little is known on the signalling processes involved in con-
trolling and coordinating all these processes, and even less
is known on the role of cAMP in this context [7,8]. Never-
theless, several independent observations indicate that
cAMP is involved in the regulation of differentiation [9-
11], but the mode of action of cAMP in these processes
remains to be explored. With respect to the generation of
the cAMP signal, adenylyl cyclases from L. donovani have
been characterized [12]. On the other hand, PDE activity
against cAMP has been demonstrated in L. mexicana and
L. donovani [13], and a PDE with an unusually high Km for
cAMP has been purified [14] from L. mexicana.
PDEs are ubiquitous enzymes, and they are essential for
cyclic nucleotide signalling since they represent, at least
for eukaryotic cells, essentially the only way for a cell to
terminate a cyclic nucleotide signal. In addition, the PDEs
are largely responsible for confining a cyclic nucleotide
signal to particular locations, and to prevent its diffusion
throughout the cell [15-17]. Three classes of PDEs have
been identified based on their different catalytic domains.
Class I [18] is found in almost all eukaryotes, and it repre-
sents the only PDE class of higher eukaryotes. Class I PDEs
have also been identified in the kinetoplastid protozoa
Trypanosoma brucei, the causative agent of African human
sleeping sickness [19-21] and Trypanosoma cruzi, the caus-
ative agent of the South American Chagas disease [22-24].
Class II PDEs [25] are found in some prokaryotes (e.g.
Vibrio fischeri) and in many lower eukaryotes such as Dic-
tyostelium discoideum or fungi such as Saccharomyces, Can-
dida or Neurospora. Dictyostelium and fungi contain genes
for both, class I and class II PDEs. A special case is repre-
sented by Schizosaccharomyces pombe that contains only a
single, class II PDE gene. The completely unrelated class
III PDEs [26] are confined to the prokaryotes.
The human genome codes for eleven PDE families, most
of which contain several family members. In addition to
this genetic variety, numerous splice variants are gener-
ated from many of the genes, resulting in a PDE proteome
of about sixty PDE isoenzymes. The catalytic domains of
all PDE family members share considerable homology in
their amino acid sequences, and their three-dimensional
structures appear to be closely similar. Despite the overall
similarity of their catalytic domains, the individual PDEs
exhibit characteristic selectivities for cAMP and/or cGMP
[27] as their substrates, and each displays a unique inhib-
itor specificity profile.
Besides their interest for basic cell biology, the human
class I PDEs have become interesting targets for drug
development. Sub-type and tissue-specific PDE inhibitors
constitute a growing class of pharmaceutical compounds
that find applications for a broad spectrum of maladies
[15,28,29].
The recent completion of a number of kinetoplastid
genomes has allowed to gain an overview over the PDE
repertoire in these organisms. We here present the identi-
fication of the five class I PDEs from Leishmania, and
report an initial characterization for three of them.
Results
Identification of five putative cyclic nucleotide specific 
PDEs of L. major
Screening the Leishmania major genome database [30]
with amino acid sequences of class I PDE catalytic
domains identified five genes that are predicted to codePage 2 of 13
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Genomic organization of PDE genesFigure 1
Genomic organization of PDE genes. Panel A: Southern blot analysis. Genomic DNA of L. major was digested with BspHI (lane 
1), BspHI plus ScaI (lane 2), BspHI plus NruI (lane 3), BspHI plus AvrII (lane 4), NotI (lane 5), NotI plus BglII (lane 6), NotI plus 
AvrII (lane 7), NotI plus ScaI (lane 8), AseI (lane 9) and SphI (lane 10). The blots was hybridized with probes B1 and B2 that spe-
cifically recognize LmjPDEB1 or LmjPDEB2, respectively (see panel B), or with probe "B" that hybridizes to both genes. The sizes 
of the DNA size markers are given on the left. Panel B: Organization of the LmPDEB locus on chromosome 15. Restriction 
sites used in the mapping are indicated. The uncharacterized stretch between the two coding regions is estimated to be about 
5 kb long. Filled boxes labelled B1, B2 and "B" indicate the gene regions used as hybridization probes. Panel C: Genomic organ-
ization of the LmjPDEB1/LmjPDEB2 locus on chromosome 15 of L. major. The organization of the corresponding loci of T. brucei 
and T. cruzi are given for comparison. T. brucei: TbrPDEB1 (old designation: TbPDE2C; Tb09.160.3590) and TbrPBEB2 (old designa-
tion TbPDE2B; Tb09.160.3630) and NHP/2RS6 (Tb09.160.3670). T. cruzi: TcrPDEB1 (Tc00.1047053508277.100) followed by 
TcrPDEB2 (old designation TbPDE1; Tc00.104053508277.120; GenBank accession number AAP49573) and by NHP2/RS6 
(Tc00.104053508277.120). Numbers indicated nucleotide positions on the respective chromosomes.
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gle copy gene LmjPDEA (GeneDB identification number:
LmjF18.1090) that is predicted to code for a polypeptide
of 631 amino acids. Its catalytic domain comprises amino
acids 384 – 609 (as defined by the conserved domain
database), with no other functional domains discernible.
The open reading frame of LmjPDEA was amplified from
genomic DNA and sequenced and its sequence was sub-
mitted to GenBank under the accession number
AY462262.
Chromosome 15 contains a locus containing two tan-
demly arranged PDE genes, LmjPDEB1 and LmjPDEB2
(Fig 1). The open reading frames of both genes were
amplified from genomic DNA and were sequenced and
the sequences have been submitted to GenBank under the
following accession numbers: LmjPDEB1: AY462264, and
LmjPDEB2: AY462263.
The sequencing data, in conjunction with Southern blot
and PCR analyses demonstrated that the current version
of the L. major database (version of July 15, 2005) con-
tains an assembly error in this region, in that it represents
only a single PDE gene that is a chimera between
LmjPDEB1 and LmjPDEB2. The genomic organization of
the LmjPDEB locus now presented in Fig 1B closely corre-
sponds to that found for the homologous PDE genes in
the T. brucei and the T. cruzi genomes. In T. brucei,
TbrPDEB1 (old designation: TbPDE2C; Tb09.160.3590)
and TbrPDEB2 (old designation: TbPDE2B;
Tb09.160.3630) are also tandemly arranged on chromo-
some 9, with 2379 bp between the two open reading
frames, followed by a gene for the small non-histone pro-
tein NHP2/RS6 (Fig 1C). In T. cruzi, the two homologues
are similarly arranged on chromosome 3, in the sequence
TcrPDEB1 (Tc00.1047053508277.100) followed by
TcrPDEB2 (old designation TcPDE1; GenBank accession
number AAP49573; [24]) and by NHP2/RS6.
LmjPDEB1 and LmjPDEB2 produce stable transcripts
Expression of the two genes in L. major promastigotes was
analyzed by Northern blot analysis and by RT-PCR. When
Northern blots of total RNA were hybridized with the
respective probes, stable mRNA was detected for both of
them (Fig. 2, panel A). Similar results were also obtained
using total RNA of L. mexicana promastigotes and amas-
tigotes (Fig. 2, panels B and C), suggesting that the two
genes are similarly expressed in both life cycle stages. The
5'-termini of the respective mRNAs in L. major promastig-
otes were analyzed by RT-PCR amplification using a com-
mon, mini-exon specific forward primer and individual
gene-specific reverse primers for each gene. For
LmjPDEB1, a single type of mRNA was found, with an
unusually long 5'-UTR region of 403 nucleotides. For
LmjPDB2, two splice variants were identified, with 5'-UTR
regions of 273 and 233 nucleotides, respectively (Fig. 3).
Northern blotsFigur  2
Northern blots. Total RNA from L. major promastigotes (panelA), L. mexicana promastigotes (panel B) and L. mexicana amastig-
otes (panel C) was fractionated on agarose gels, and the RNA-filters were hybridized with DIG-labelled DNA probes for 
LmjPDEB1 (B1) and LmjPDEB2 (B2). The sizes of the two mRNAs were 5.3 Kb and 4.9 Kb for B1 and B2, respectively.
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LmjPDEB2
The polypeptide chain of LmjPDEA consists of 631 amino
acids without any recognizable functional domain, except
for the class I PDE catalytic domain at the C-terminus
(amino acids 384 – 609).
The open reading frames of LmjPDEB1 (2820 bp) and
LmjPDEB2 (2790 bp) code for proteins of 940 and 930
amino acids, respectively. The two share an overall 82 %
sequence identity, with a markedly uneven distribution
along the polypeptides. The first 230 amino acids are
highly diverged (only 34 % amino acid sequence iden-
tity), whereas the remainder of the sequence is almost
completely conserved (96.6 % sequence identity). The
only exception is a stretch of 24 amino acids in the cata-
lytic domain that are entirely dissimilar between
LmjPDEB1 and LmjPDEB2 (Fig. 4). Interestingly, similar
stretches of divergence within the catalytic domains are
also found, at identical positions, in the respective homo-
logues of T. brucei and T. cruzi. LmjPDEB1 and LmjPDEB2
both contain two closely spaced GAF domains [31] in
their N-terminal regions (LmjPDEB1: GAF-A amino acids
250-398, GAF-B 422 – 567; LmjPDEB2: GAF-A: 240 –
388, GAF-B: 412 -557). Between the two GAF domains, a
putative protein kinase A phosphorylation site is located
(KKKS; LmjPDEB1 402 – 404; LmjPDEB2 392 – 395).
This is the only protein kinase A site that is also conserved,
and found at an identical position, in the T. brucei and T.
cruzi homologues.
The catalytic domains of the leishmanial PDEs are highly
conserved, and they all contain the signature sequence
[HD(LIVMFY)XHX(AG)XXNX(LIVMFY)] that character-
izes them as class I PDEs [18]. The amino acid sequence
identity between the catalytic domains of LmjPDEB1 and
LmjPDEB2 and the corresponding regions of the human
PDEs 1 – 11 varies between 41.7% (to HsPDE3A) to
48.9% (to HsPDE10A). Based on the publicly available
3D-structures of several human PDE catalytic domains
[32], sixteen amino acid residues are absolutely conserved
between all human PDEs (Table 1). In only two of these
positions, some of the leishmanial PDEs exhibit amino
acid replacements, both in positions that are not directly
located in the active site. A conserved alanine residue
(A466 in HsPDE4B) is replaced by G741, G731 and Y673 in
5'-UTR sequences of LmjPDEB1 and LmjPDEB2Figure 3
5'-UTR sequences of LmjPDEB1 and LmjPDEB2. Larger, bold letter indicate the various splice acceptor sites. Bold, underlined 
letters symbolize the start of the open reading frames.
LmjPDEB2
-273 TGCGTGCGTG CGTGTGTGTG TGTGTGTGTG CGCACGTCAG AACCGTCTCA
-223 AGTCCCTCAC CTCAGCGTCA ATCTACCCTC ATTGTCGTCG TCGGCCTTGA
-173 CGTGTTTTCG GTCATCGTTT CACCATTGTC TCGGCTCAAC GACCACAATA
-123 GAAAAAAGCA TAGGGATCGG AAAGCTGTGG CCTATACACG TTCACGGGTG
-73 CCCGCTCAGC GCTGGACACG TGCGCACGTC CACCGCATCA CAGTGAGAGA
-23 CGGAGAGAAA CCAGCGTAGC GCCATGG
-403 TGCGCCTCTC GCTTCTCCAG CTCCACACGC GCTCACTGGC CATCATCAAA
-353 GGGAAGCCAC CATCGGCACC CAAGGAGCTT AACCAGCATT TGAGGTTCTT
-303 CAAAAGGCGG TGTGAGGTGC AGCTGCACTG GATCATTCGG GGGACACAAA
-253 CGCGCATGCG TGCACGGCTG CACACGGGAC CCGTCATTGT CTCTTCCGCT
-203 CTGTTGCTCC TGTCGCCGCT CTCCACAGCG ACACACATAC ACACACAGTC
-153 AGACACACAC ACACACACAC ACACACACAA GCGAGCCCCA TACACGCAAA
-103 CGCCACGCGG CCTCTTTGTT GTTCGTTTGT TCGCTCTTGT TTTTCGGCTC
-53 GTATTGGCCG CTGTCTTCGA TTTGTTATCA ACTGGCAGTG ACGCCGTACA
-3 GCGATGC
LmjPDEB1Page 5 of 13
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addition, a conserved histidine residue (H478 in
HsPDE4B) is replaced by leucine (L459 in LmjPDEA) or
methionine (M685 in LmjPDEC). Of the two residues that
confer selectivity for cAMP over cGMP, Q443 and N567 in
HsPDE4B [33], the glutamine residue is conserved in all
leishmanial PDEs. In the position corresponding to N567,
an asparagine residue is maintained in all leishmanial
PDEs except for LmjPDEC. Here the corresponding posi-
tion is taken by an alanine residue (A770 in LmjPDEC).
This suggests that LmjPDEC might represent a dual-sub-
strate PDE, as has already been experimentally demon-
strated for its T. cruzi homologue, TcrPDEC [22]. While
the catalytic domains of all five L. major PDEs share a high
degree of similarity, the two catalytic domains of
LmjPDEB1 and LmjPDEB2 are completely identical, with
the exception of a stretch of 24 amino acids that com-
prises the predicted helices 12 and 13. Similar non-con-
served stretches of comparable length and at identical
locations are also observed in the homologues of T. brucei
and T. cruzi (Fig 4).
Functional complementation of a PDE-deficient S. 
cerevisiae strain by LmjPDEA, LmjPDEB1 and LmjPDEB2
Deletion of the two PDE genes ScPDE1 and ScPDE2 from
the S. cerevisiae genome renders the mutants highly sensi-
tive to stress conditions such as a heat-shock. Heterolo-
gous complementation of this heat-shock phenotype has
proven to be a highly sensitive validation procedure for
suspected PDE genes [19,34]. The full-size open reading
frames of LmjPDEA, LmjPDEB1 and LmjPDEB2 were
cloned into the yeast expression vector pLT1 [19] and
expressed in the PDE-deficient S. cerevisiae strain PP5 [35].
Transformants were patched and tested for heat shock
resistance (Fig 5). All three PDE genes restored heat shock
resistance to the indicator strain, though with different
efficiencies. LmjPDEB1 and LmjPDEB2 completely
restored the wild-type phenotype, whereas complementa-
tion by LmjPDEA was much weaker, as seen at short incu-
bation times after the heat shock. Patches expressing
LmjPDEA had only grown weakly when observed after 18
h post-heat-shock incubation at 30°C (Fig. 5B), while
patches expressing LmjPDEB1 or LmjPDEB2 already
showed vigorous growth after this time. When observed
after 36 h of incubation, all three recombinant strains had
grown to a similar extent (Fig. 5D). The results of these
complementation experiments established that all three
Sequence organization and comparison of LmjPDEB1 and LmjPDEB2Fig re 4
Sequence organization and comparison of LmjPDEB1 and 
LmjPDEB2. Panel A: Extent of amino acid sequence identity 
between various parts of LmjPBEB1 and LmjPDEB2. A 24 
amino acid stretch within the otherwise identical catalytic 
region is entirely dissimilar between the two. Panel B: similar 
stretches of sequence divergence (boxed area) are found at 
identical positions within the otherwise highly conserved cat-
alytic regions the T. brucei and T. cruzi homologues. 1: 
TbrPDEB1; 2: TbrPDEB2; 3: LmjPDEB1; 4: LmjPDEB2; 5: 
TcrPDEB1; 6: TcrPBEB2.
GAF-A GAF-B catalytic
34%
96.6%
16.7%
1.  777 IDCVLATDMAKHGSALEAFLASAAD-QSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQ
2.  777 IDCVLATDMARHSEFLEKYLELMKTSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQ
3.  789 IDCVLATDMAKHADALSRFTELATSGFEKDNDTHRRLVMETLIKAGDVSNVTKPFETSRM
4.  779 IDCVLATDMARHGDLSRVFDDMAKAGYDSNDQESRRLVMETLIKAGDVSNVTKPFETSRM
5.  777 IDCVLATDMAKHGKSLESFLSVLGNP-ETSEQRIAELTMQIVLKAGDVSNVTKPFDISRL
6.  780 IDCVLATDMAKHNELLNLFLAAMEKPYQIGDVASRQMMMETLIKAGDVSNVTKPFETSRM
PKA-siteA
B
Table 1: Amino acid replacements of conserved residues in the catalytic domains of L. major PDEs. Amino acid conservation is 
indicated by a dash.
HsPD
E4B
Y399 H406 N407 H410 H446 D447 H450 G452 A466 E476 H478 H479 T517 D564 E585 Q615
LmjP
DEA
- - - - - - - - - - L459 - - - - -
LmjP
DEB1
- - - - - - - - G741 - - - - - - -
LmjP
DEB2
- - - - - - - - G731 - - - - - - -
LmjP
DEC
- - - - - - - - Y673 - M685 - - - - -
LmjP
DED
- - - - - - - - - - - - - - - -Page 6 of 13
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BMC Microbiology 2006, 6:25 http://www.biomedcentral.com/1471-2180/6/25genes code for functional PDEs, and they demonstrate
that these PDEs can use cAMP as their substrate.
Catalytic activity
Soluble cell lysates were prepared from yeast strains
expressing each of the three PDEs and were assayed for
PDE activity. Lysates prepared from the LmjPDEA express-
ing strain consistently showed no measurable PDE activ-
ity. While the reason for this is still unclear and might
reflect a trivial technical problem, the observation is in
line with the finding that LmjPDEA complements the
PDE-deficient yeast strain PP5 much less efficiently than
do the two other PDE genes (see Fig. 5). In contrast to
LmjPDEA, lysates from yeast strains expressing LmjPDEB1
and LmjPDEB2 showed strong PDE activities. The two
enzymes exhibit Km values of 1 and 7 µM for cAMP,
respectively, well within the range of other class I PDEs
(Table 2). The apparent Km for cAMP (0.97 ± 0.09 µM)
was not altered by the presence of a 100-fold excess of
cGMP (Fig 6A and 6B), nor was Vmax (2.56 ± 0.71 nmol/
mg lysate/15 min), indicating that LmjPDEB1 and
LmjPDEB2 are specific for cAMP, and that their activity is
not modulated by cGMP. A 50-fold excess of the reaction
product 5'-AMP also did not alter the Km (Fig 6C), indicat-
ing that the PDEs are not subject to marked product inhi-
bition. For all parameters determined, LmjPDEB1 and
LmjPDEB2 behaved very similarly, indicating that the
small stretch of sequence divergence between the two cat-
alytic domains does not markedly alter their functionality.
Also, the divergent N-terminal regions do not seem to
affect the kinetics under in vitro conditions.
Inhibitor profiling
As an initial survey, a number of commercially available
inhibitors that are frequently used in cell biological stud-
ies were tested at a 100-fold excess over substrate (100 µM
inhibitor vs 1 µM cAMP; Fig. 6D), using extracts from
yeast cells expressing the recombinant PDEs. Most of the
inhibitors tested (cilostamide, zaprinast, etazolate, dipyri-
damole, Ro-20-1724, rolipram, isobutyl-methylxanthine
(IBMX), 8-methoxymethyl-IBMX, trequinsin, papaverine,
milrinone, pentoxifylline, and erythro-9-(2-hydroxy-3-
nonyl)adenine (EHNA) were essentially inactive, even at
the high concentration used in these experiments. Only
dipyridamole (IC50 = 29 µM), trequinsin (IC50 = 96 µM)
and etazolate caused significant inhibition.
Inhibition of cell proliferation
Dipyridamole, etazolate and trequinsin were further
tested for their effect on cell proliferation (Fig. 7). Promas-
tigote cultures of L. major or amastigote cultures of L.
infantum were grown in the presence of various concentra-
tions of inhibitors, or in the presence of 1 % (v/v) dimeth-
ylsulfoxide as a control. All three compounds were
strongly inhibitory (IC50 dipyridamole = 44.7 ± 12.2 µM; IC50
etazolate = 57.5 ± 27.0 µM; IC50 trequinsin = 43.6 ± 3.7 µM for
promastigotes; and IC50 trequinsin = 10.2 ± 4.2 µM for amas-
tigotes, respectively). All three inhibitors are markedly
more potent than the frequently used, wide-spectrum
PDE-inhibitor isobutyl-methyl-xanthine (1.03 ± 0.67
mM). The inhibitory effects were independent of cell den-
sity and were not reduced upon prolonged incubation of
the culturesThese observations indicate that the inhibitors
are metabolically stable, and that the PDEs may be of sim-
ilar importance for proliferation of both promastigotes
and amastigotes in culture.
Discussion
The current study reports on the identification and charac-
terization of three class I cyclic nucleotide-specific PDEs
from L. major. LmjPDEA is a single copy gene, while the
two genes for LmjPDEB1 and LmjPDEB2 are tandemly
arranged on chromosome 15 and code for two similar
enzymes. Very similar enzymes also have been identified
in T. brucei and other kinetoplastids, and a unifying
nomenclature for kinetoplastid PDEs has recently been
Complementation of the PDE-deficient S. cerevisiae strain PP5Figure 5
Complementation of the PDE-deficient S. cerevisiae strain 
PP5. Panel A: plate without heat-shock treatment, incubated 
at 30°C for 18 h; panels B – D: plates heat-shocked for 15 
min at 55°C, and subsequently incubated at 30°C for 18 h 
(panel B), 24 h (panel C) or 36 h (panel D). The plates always 
display rows of patches of two independent transformants 
transfected with the following plasmids: Row 1: pLT1 + TbrP-
DEA (= positive control); row 2: pLT1, empty plasmid (= neg-
ative control); row 3: pLT1 + LmjPDEA; row 4: pLT1 + 
LmjPDEB2; row 5: pLT1 + LmjPDEB1.
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PDEs are very similar to those of the human PDEs, and all
functionally important amino acids are conserved.
LmjPDEA, LmjPDEB1 and LmjPDEB2 complement the
PDE-defective S. cerevisiae strain PP5 and restore its wild-
type heat-shock resistance phenotype. However, comple-
mentation by LmjPDEA was less effective (slower cell
growth after heat shock) than that by the other two (see
below). When yeast cell lysates were prepared from LmjP-
DEA-complemented strains, no PDE activity was detecta-
ble. This is similar to what was observed earlier with the
highly conserved T. brucei homologue of LmjPDEA. This
gene, TbrPDEA, also complements the PP5 strain, but only
very little enzyme activity was detectable in yeast cell
lysates [19]. This lack of biochemically detectable activity
despite functional complementation may reflect some
specific property common to the LmjPDEA and TbrPDEA
enzymes.
LmjPDEB1 and LmjPDEB2 contain catalytic domains that
are identical, except for a 24 amino acid sequence that is
highly diverged between the two. This sequence spans the
region of predicted helices 12 and 13 [32]. Divergent
regions of similar length are also found at the correspond-
ing locations of the homologous PDEs of T. brucei and T.
cruzi (see below). These regions might confer subtle func-
tional or regulatory specificities to the otherwise highly
conserved catalytic domains of the respective isoenzymes
of each species.
For LmjPDEB1 and LmjPDEB2 highly conserved, homo-
logues genes exist also in other kinetoplastid protozoa, T.
brucei and T. cruzi. In both organisms, the two homo-
logues TbrPDEB1 (old nomenclature: TbPDE2C [20]) and
TbrPDEB2 (old nomenclature: TbPDE2B [21]) on chro-
mosome 9 of T. brucei, and TcrPDEB1 and TcrPDEB2 (old
nomenclature: TcPDE1 [24]) on chromosome 3 of T. cruzi
are tandemly arranged with the two open reading frames
spaced by about 2500 bp, and followed by an open read-
ing frame of an NHP2/RS56 gene coding for a non-histone
protein. Our results suggest that LmjPDEB1 and
LmjPDEB2 are similarly arranged on chromosome 15 of L.
major.
LmjPDEB1 and LmjPDEB2 both complement the PDE-
deficient yeast strain PP5 very effectively, and high
enzyme activities were present in the respective yeast cell
lysates. Both enzymes behave very similarly, exhibiting
Kms in the low µM range for cAMP as a substrate, and they
are entirely specific for cAMP. When a number of PDE
inhibitors were tested on recombinant LmjPDEB1 and
LmjPDEB2, most of them exhibited very low potency.
This marked insensitivity of leishmanial PDEs to many
PDE inhibitors, including the broad-spectrum inhibitor
IBMX, corresponds to what was found with the T. brucei
homologues. Only dipyridamole, trequinsin and eta-
zolate exhibited at least a moderate potency.
The three inhibitors also inhibited proliferation of L.
major promastigotes in culture, all with IC50 values in the
30 – 100 µM range. Very similar EC50 values are also
obtained when the same compounds were used with L.
infantum amastigotes, indicating that both life cycle stages
are similarly sensitive to these inhibitors. Though inhibi-
tor specificity cannot be taken for granted at these rela-
tively high concentrations, the experiments clearly suggest
Table 2: Km of PDEs
PDE cAMP (µM) cGMP (µM) Refs
LmPDEB1 0.99 --- *)
LmPDEB2 6.98 --- *)
TbrPDEB1/TbPDE2C 7.97 --- [20]
TbrPDEB2/TbPDE2B 2.4 --- [21]
HsPDE1A1 112.7 5.0 [38]
HsPDE1B1 24.3 2.7 [38]
HcPDE1C2 1.2 1.1 [38]
HsPDE2 30 – 50 15 – 30 [38]
HsPDE3 0.1–0.8 0.1– 0.8 [38]
HsPDE4 1 – 3 --- [38]
HsPDE5 > 300 1 – 5 [38]
HsPDE6 910 14 [39]
HsPDE7 0.2 – 1 --- [38]
HsPDE8 0.06 – 0.15 124 [38]
HsPDE9 320 0.007–0.17 [38]
HsPDE10 0.05 3 [38]
HsPDE11 0.5 1 [38]
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blocks cell proliferation.
Conclusion
The identification and molecular characterization of the
leishmanial PDEs will now allow a more detailed investi-
gation of the role of cAMP signalling in Leishmania biol-
ogy. On the other hand, these PDEs may represent novel
drug targets. They belong to a family of enzymes that has
already been successfully exploited by medicinal chemis-
try for a number of human disease conditions. The range
of applications for PDE inhibitors might yet be extended
further to include antiprotozoal drugs.
Methods
Materials
3H-labeled cAMP was purchased from Hartmann Analyt-
ics, Braunschweig, Germany (Cat. Nr MT 616, 15-50 Ci/
mmol). After purification by ion-exchange chromatogra-
phy on QAE-Sephadex A25, it was stored frozen at -20°C.
Oligonucleotide primers were purchased either from
Microsynth, Balgach, Switzerland, or from Qiagen. DNA
sequencing was done using the ABI Prism BigDye Termi-
nator v3.0 Cycle Sequencing Ready Reaction Kit (Applied
Biosystems). Sequences were analyzed on an ABI 3100
instrument at the Computational and Molecular Popula-
tion Genetics Lab, University of Bern.
Characterization of PDE activity and inhibitor potencyFigure 6
Characterization of PDE activity and inhibitor potency. Panel A: Michaelis-Menten kinetics of recombinant LmjPDEB2 with 3H-
cAMP as substrate. Panel B: reaction in the presence of a 100-fold excess of unlabelled cGMP. Panel C: reaction in the pres-
ence of a 50-fold excess of unlabelled AMP. Inserts in A – C: corresponding Eadie-Hofstee plots. Panel D: Effect of PDE inhibi-
tors on LmjPDEB2 activity (1 µM 3H-cAMP substrate, 100 µM inhibitor). 1, cilostamide; 2, zaprinast; 3, etazolate; 4, 
dipyridamole; 5, Ro-20-1724; 6, rolipram; 7, IBMX; 8, 8-methoxy-methyl-IBMX; 9, trequinsin; 10, papaverine; 11, milrinone; 12, 
pentoxifylline; 13, erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA). Very similar results were obtained with LmjPDEB1.
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Leishmania major MHRO/IR/75/ER or LV39 promastigote
forms were cultivated at 27°C in SDM medium contain-
ing 5% heat-inactivated foetal bovine serum [37]. The
MHRO/IR/75/ER isolate was originally recovered from a
patient in Iran, and was obtained through Nicolas Fasel,
Dept. of Biochemistry, University of Lausanne. Cell prolif-
eration assays were done in 5 ml cultures to which drugs
dissolved in DMSO were added. The final DMSO concen-
tration was 1 % in all cases, and appropriate DMSO con-
trols were always included. At various times, 150 ml
aliquots were withdrawn and absorbance was measured at
600 nm in a microtiter plate reader. The correlation
between OD600 and cell number was strictly linear over at
least the range between 3 × 105 and 4 × 107 cells/ml.
Identification and cloning of PDE genes
The Leishmania genome database [30] was searched with
the amino acid sequences of the cAMP-specific PDEs from
Trypanosoma brucei TbrPDEA (old nomenclature: TbPDE1;
GenBank accession number AAL58095) and TbrPDEB1
(old nomenclature: TbPDE2C; GenBank accession
number AAK33016). The genes to be characterized in this
study were named LmjPDEA, LmjPDEB1and LmjPDEB2,
in accordance with the recently proposed unified nomen-
clature [36]. Based on the database sequences, PCR prim-
ers were designed to amplify the open reading frames of
Inhibition of cell proliferation in cultureFigure 7
Inhibition of cell proliferation in culture. The EC50 values for L. major promastigote proliferation were determined for dipyrida-
mole (panel A), etazolate (panel B) and trequinsin (panel C). Panel D represents an EC50 determination for trequinsin with L. 
infantum amastigotes. EC50 values were determined various time points and cell densities, and all growth experiments were 
repeated at least three times. Representative growth curves for each inhibitor are shown. EC50 values for all inhibitors were in 
the 30 – 100 µM range for both promastigotes and amastigotes.
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for LmjPDEA, LmjPDEB1 and LmjPDEB2, respectively
were LmPDEAup1 (5'-GTGGTCGACTCGACTTTCTT-
GAGCAG-3'), LmPDEB2up1 (5'-GATGTCGACAT-
TCAGCGGTCTTTTCC-3') and LmPDEBup1 (5'-
GATGTCGACTGGCATATTTCACGGCCA-3'). All con-
tained a SalI site (underlined) followed by the respective
gene sequence without the start codon (boldface type).
The reverse primers for LmjPDEA, LmjPDEB1 and
LmjPDEB2, respectively were LmPDEAlo1 (5'-
CTGGGAATCCTAAGCATAATCTGGAACATCATATGGA-
TACGAGTCGTCGTGGTTGG-3'), LmPDEB2lo1 (5'-
CTGGGAATCCTAAGCATAATCTGGAACATCATATGGA-
TAAACAATCGAGGATCGGATG-3') and LmPDEBlo1 (5'-
CTGGGAATC CTAAGCATAATCTGGAACATCATATGGA-
TAAACAATCGAGGGTCGGATG-3'). . All reverse primers
contained a stop codon (underlined) and a preceding
sequence coding for a hemagglutinin tag (-YPYDVPDYA;
in italics), followed by the gene-specific sequence (bold-
face). PCR products with sizes of 1.9 kbp (LmjPDEA) and
2.8 kbp (LmjPDEB1 or LmjPDEB2) were cloned into the
pCR2.1 vector (Invitrogen) and were verified by sequenc-
ing.
Southern blot analysis
Genomic DNA was isolated from L. major promastigotes,
digested with the appropriate restriction enzymes, sepa-
rated on 0.8 % agarose gels and transferred to a positively
charged nylon membrane (Roche). Digoxigenin-labelled
DNA probes were generated using the PCR DIG probe
synthesis kit (Roche). Probes were amplified with the fol-
lowing primers: LmPDEAup5 (5'-TAACCACCCGAAG-
GAGTACG-3') and LmPDEAlo5 (5'-
CTCGGCTACCTGAGAGTTGG-3'), resulting in a fragment
of 449 bp specific for LmjPDEA; LmPDEB2up6 (5'-
CGTCGGACTGGTACATCCTT-3') and LmPDEB2lo6 (5'-
GTTTGCGATCACCATGTACG-3') produced a 312 bp frag-
ment specific for LmjPDEB1; LmPDEBup5 (5'-CTGCAT-
TCTGAGCCGTTACA-3') and LmPDEBlo5 (5'-
AATGGTAACGGTCGTCTTCG-3') produced a 394 bp
fragment specific for LmjPDEB2. A hybridization probe
recognizing both genes, LmjPDEB1 and LmjPDEB2, was
amplified by PCR with the primers LmPDEBup6 (5'-CCT-
GCAGCGTAACAGCATTA-3') and LmPDEBlo6 (5'-
GCGAGTCCGTCTTCAGGTAG-3'; fragment length 476
bp). In order to achieve a minimal hybridization back-
ground, the DNA templates for the PCR reactions were
excised from the respective plasmid vectors by digestion
with BamHI and SalI and were purified by gel extraction
(QIA quick Gel Extraction Kit, Qiagen). Blots were prehy-
bridized for 6 h in DIG Easy Hyb buffer (Roche) and were
hybridized at 42°C overnight in the same buffer contain-
ing 20 ng/ml of DIG-labelled probe. High stringency
washes were done in 0.5 × SSC, 0.1 % SDS at 68°C twice
for 15 min. Hybridization signals were detected with an
alkaline phosphatase-conjugated anti-DIG antibody
(Roche) and the CDP-Star substrate (Roche) and were vis-
ualized on a LAS-1000 Image Reader (Fuji).
Northern blot analysis
Total RNA from L. major promastigotes or L. mexicana
amastigotes was denatured in 50 % (v/v) DMSO, 4 % (v/
v) deionised glyoxal and 10 mM sodium phosphate, pH
6.85, for 5 min at 50°C and separated on a 1.2 % agarose
gel in 10 mM sodium phosphate. RNA was transferred to
positively charged nylon membranes (Roche) by capillary
force. Prehybridization and hybridization with the DIG-
labelled probes were done as described above, but at a
hybridisation temperature of 50°C. High stringency
washes and hybridisation signal detection were done as
described above. A hybridization probe specific for α-
tubulin was used to normalize all blots.
Expression in S. cerevisiae
The leishmanial PDEs were expressed in the PDE-deficient
S. cerevisiae strain PP5 (MATa leu2-3 leu2-112 ura3-52
his3-532 his4 cam pde1::ura3 pde2::HIS3), a gift of John
Colicelli (UCLA). The hemagglutinin-tagged, full-length
PDE genes were excised from the cloning vectors by diges-
tion with BamHI and SalI, purified by gel extraction and
introduced into the yeast expression vector pLT1 [19]. The
pLT1 vector contains a strong TEF 2 promotor, followed
by an optimized Kozak sequence, the start codon and a
SalI site (5'-CTAAACATGGTCGAC-3'; Kozak sequence in
italics, start codon in boldface and SalI site underlined).
Transformation into the yeast strain PP5 was done exactly
as described [19].
Complementation assay
The heat-shock assay to detect complementation of the
PDE-deficient phenotype of the S. cerevisiae strain PP5 was
done exactly as described [19]. Single yeast colonies were
patched onto YPD plates prewarmed to 55°C, and were
incubated for another 15 min at 55°C. Plates were then
cooled to room temperature and were incubated at 30°C
for 18 – 36 h.
Yeast cell lysis
Yeast cell lysis was performed as described by Kunz et al
[19] with minor modifications. Briefly, yeast cells grown
to mid-log to end-log phase in SC-leu medium were col-
lected, resuspended in the original volume of prewarmed
YPD medium, and incubated for an additional 3.5 h at
30°C to maximize protein expression. Cells were then
harvested and washed twice in H2O, and the washed cell
pellet was stored overnight at -70°C. For preparing the
lysate, the cells were thawed on ice and suspended in ice-
cold extraction buffer (50 mM Hepes pH 7.5, 100 mM
NaCl, 1 × Complete® protease inhibitor cocktail without
EDTA (Roche)). Cells were lysed by grinding with glassPage 11 of 13
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FastPrep FP120 cell disruptor (3 × 45 s at setting 4). The
subsequent centrifugation steps were done exactly as
described. To the resulting supernatant, glycerol was
added to a final concentration of 15 % (v/v), aliquots
were snap-frozen in liquid nitrogen and were stored at -
70°C.
Phosphodiesterase assay
PDE activity was determined in 50 mM HEPES, pH 7.5,
0.5 mM EDTA, 10 mM MgCl2, 50 mg/ml BSA in a final
assay volume of 100 µl. Each assay contained 50'000 cpm
3H-labelled cAMP, with unlabeled cAMP added to adjust
the desired total substrate concentration. Reactions were
run at 30°C and were linear for at least 60 min. The stand-
ard reaction time was set to 15 min, and the amount of
enzyme was always chosen so that no more than 15 % of
the substrate was hydrolyzed. Inhibitor studies were done
at a cAMP concentration of 1 µM. Inhibitors were dis-
solved in DMSO, but the final DMSO concentration in the
assays never exceeded 1%. Control reactions with DMSO
alone were always included. Reactions were stopped by
the addition of 25 µl of 0.5 N HCl. For the subsequent
dephosphorylation of the AMP, the stopped reactions
were neutralized with 20 µl 1 M Tris base, followed by the
addition of 10 µl of calf intestinal alkaline phosphatase
(Roche Diagnostics; 1 unit/10 µl). The dephosphoryla-
tion reactions were incubated for 15 min at 37°C and
were then applied to 1 ml columns of QAE-Sephadex A25
in 30 mM ammonium formiate, pH 6.0. The 3H-adenos-
ine formed during the reaction was eluted with 1.6 ml of
30 mM ammonium formiate, pH 6.0 and was collected
into 3.5 ml water-miscible scintillation fluid (Packard
Ultima Flo). Assays were always run in triplicates, and at
least three independent experiments were performed in
every case. Data were analyzed using the GraphPad Prism
software package.
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